Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Chimeric antigen receptor (CAR) modified T cell therapy has revolutionized the treatment of relapsed and refractory hematological malignancies. Through targeting of the CD19 antigen on B cells durable remissions have been achieved in patients with B cell non-Hodgkin lymphoma and acute lymphoblastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Nirav N., Maatman, Theresa, Hari, Parameswaran, Johnson, Bryon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423158/
https://www.ncbi.nlm.nih.gov/pubmed/30915277
http://dx.doi.org/10.3389/fonc.2019.00146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423158/
https://www.ncbi.nlm.nih.gov/pubmed/30915277
http://dx.doi.org/10.3389/fonc.2019.00146

Ejemplares similares